Answer
The safety and efficacy of selexipag in children aged 2 to under 18 years have not yet been established, no dosing recommendation can be made, and paediatric administration is not recommended.
Sources for this answer
- Uptravi 200 microgram film-coated tablets (Great Britain)Janssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.2 Posology and method of administration · Version 19Document updated
Sources checked